As­traZeneca cel­e­brates a PhI­II PARP suc­cess for Lyn­parza, putting pres­sure on Tesaro ri­val

As­traZeneca dropped one very big, tan­ta­liz­ing clue this morn­ing that will de­ter­mine the fate of its PARP in­hibitor Lyn­parza (ola­parib). As ri­val PARPs come up the pipeline from Tesaro, Clo­vis and Pfiz­er, the phar­ma gi­ant says that its Phase III ovar­i­an can­cer study came up with sta­tis­ti­cal­ly sig­nif­i­cant re­sults that beat out what we’ve seen so far.

“Im­por­tant­ly, the me­di­an PFS in the Lyn­parza arm of SO­LO-2 sub­stan­tial­ly ex­ceed­ed that ob­served in the Phase II main­te­nance study in pa­tients with plat­inum-sen­si­tive re­lapsed ovar­i­an can­cer (Study 19),” As­traZeneca $AZN said in a re­lease. In­ves­ti­ga­tors test­ed the drug as a main­te­nance monother­a­py com­pared with place­bo in pa­tients with plat­inum-sen­si­tive re­lapsed or re­cur­rent BR­CA-mu­tat­ed (BR­CAm) ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER